LED medical treatments approved by FDA

The US Food and Drug Administration has given clearance for two different LED systems to be marketed for medical applications.

Content Dam Leds En Articles 2005 01 Led Medical Treatments Approved By Fda Leftcolumn Article Thumbnailimage File
The US Food and Drug Administration (FDA) has approved given clearance for Light BioScience, LLC (Virginia Beach, VA) to market its GentleWaves LED Photomodulation System for the non-invasive treatment of periorbital (eye area) wrinkles.

GentleWaves
The system provides cosmetic improvement of aging and sun-damaged skin. During treatment, the patient is exposed to two panels of over 2000 yellow LEDs for less than l minute. The low-energy light stimulates collagen and reverses the appearance of photo-induced aging.

"For the first time, we are both slowing down collagen breakdown and building up new collagen with no pain, no redness and no serious side effects," said Robert Weiss, MD, associate professor of dermatology at Johns Hopkins University School of Medicine.

Infrared pain treatment

BioCare Systems of Denver, Colorado, has received clearance from the FDA to market its LED-based PremIR818(TM) Infrared Therapy device for the temporary relief/reduction of minor pain or discomfort associated with muscles including neck and back pain caused by muscle tension, joints, arthritis, sprains and strains.

The system uses low-intensity infrared light from an LED source to stimulate natural biological processes in the area where the light is applied. Referred to as "photobiomodulation" and "photobiostimulation," this process promotes the body's own natural healing and tissue immune responses.

"BioCare has improved upon the proven technology of the science of photobiomodulation and developed a medical device for the consumer market using LEDs in place of laser technology," said Sherry Fox, BioCare's president and CEO. "LED light is safer, less expensive and often as effective as the more highly complex technology used in clinical settings."

BioCare's patented emitter technology uniquely addresses issues of treatment modality, power deposition rate, optimal source wavelength, dosage duration and specific indication parameters. The LED wavelength falls within the optimal range for absorption of light by oxygenated hemoglobin to promote maximal photobiostimulatory effects while still allowing adequate tissue penetration. At the same time, this wavelength is poorly absorbed by water, resulting in little direct heating of tissue, and therefore, minimal risk of heat-induced tissue damage.

More in Facade & Entertainment